Abstract:Brain aging is characterized by a decrease in N‐methyl D‐aspartate mediated glutamate‐stimulated release of norepinephrine in the cerebral cortex. Proposed target sites for pharmacological restoration of deficits in norepinephrine release in the aging brain include blockade of alpha‐2 adrenergic receptors using mirtazapine or idazoxan, and targeting the norepinephrine reuptake inhibitor with the CNS stimulant methylphenidate. Aging affects virtually all organs of the body, but perhaps it has the most profound effects on the brain and its neurotransmitter systems, which influence a wide range of crucial functions, such as attention, focus, mood, neuroendocrine and autonomic functions, and sleep cycles. All of these essential functions, as well as fundamental cognitive processes such as memory, recall, and processing speed, utilize neuronal circuits that depend on neurotransmitter signaling between neurons. Glutamate (Glu), the main excitatory neurotransmitter in the CNS, is involved in most neuronal excitatory functions, including release of the neurotransmitter norepinephrine (NE). Previous studies from our lab demonstrated that the age‐associated decline in Glu‐stimulated NE release in rat cerebral cortex and hippocampus mediated by NMDA glutamate receptors, as well as deficits in dendritic spines, and cognitive functions are fully rescued by the CNS stimulant amphetamine. Here we further investigated Glu‐stimulated NE release in the cerebral cortex to identify additional novel target sites for restoration of Glu‐stimulated NE release. We found that blockade of alpha‐2 adrenergic receptors fully restores Glu‐stimulated NE release to the levels of young controls. In addition, we investigated the density and responsiveness of NMDA receptors as a potential underlying neuronal mechanism that could account for the observed age‐associated decline in Glu‐stimulated NE release. In the basal state of the receptor (no added glutamate and glycine) the density of NMDA receptors in the cortex from young and aged rats was similar. However, in contrast, in the presence of 10 μM added glutamate, which opens the receptor channel and increases the number of available [3H]‐MK‐801 binding sites within the channel, the density of [3H]‐MK‐801 binding sites was significantly less in the cortex from aged rats.

CYP3A Mediated Ketamine Metabolism is Severely Impaired in Liver S9 Fractions from Aging Sprague Dawley Rats

Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans

The Variability in CYP3A4 Activity Determines the Metabolic Kinetic Characteristics of Ketamine.

Pharmacokinetics and drug metabolism in the elderly

Mechanism of low-dose ketamine-induced reduction of cognitive dysfunction following sevoflurane anesthesia in aged rats: plasticity of dendritic spines in entorhinal cortical neurons

Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs

Differential Susceptibility to Propofol and Ketamine in Primary Cultures of Young and Senesced Astrocytes

Fast-acting antidepressant-like effects of ketamine in aged male rats

Aging Affects the Drug Metabolism Systems of Rat Liver, Kidney, Colon and Lung in a Differential Fashion

Function of 38 Variants CYP2C9 Polymorphism on Ketamine Metabolism in Vitro

Reduced Dorsal Prefrontal Gray Matter after Chronic Ketamine Use.

Effects of Ketamine and Splenectomy on Cognition and Synaptic Plasticity in Hippocampus of Senile Rats

Liver Function and Phase I Drug Metabolism in the Elderly

Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions

Pharmacological target sites for restoration of age‐associated deficits in NMDA receptor‐mediated norepinephrine release in brain

Ketamine alters cortical integration of GABAergic interneurons and induces long-term sex-dependent impairments in transgenic Gad67-GFP mice

The effect of aging on the repeated-dose liver micronucleus assay using N-nitrosodipropylamine, quinoline, and carbendazim

(R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency

Role of Different Doses of Ketamine in Postoperative Neurocognitive Function in Aged Mice Undergoing Partial Hepatectomy by Regulating the Bmal1/NMDA/NF-Κb Axis

Mechanism of Cognitive Dysfunction Alleviation After Sevoflurane Anesthesia in Aged Rats Through Low-Dose Ketamine Based on the PI3K/Akt Pathway